基于FRAX®干预阈值管理新加坡女性骨质疏松的成本效益
该成本效益分析采用经验证的马尔可夫微观模拟模型,评估新加坡50岁以上女性使用仿制阿仑膦酸钠相比不治疗的成本效益。结果显示,在年龄依赖性主要骨质疏松性骨折干预阈值下,自65岁起具有成本效益;在髋部骨折干预阈值下,完全依从和真实世界依从分别自60岁和65岁起具有成本效益。仅在固定主要骨质疏松性骨折阈值14%和髋部骨折阈值3.5%时,阿仑膦酸钠在任何年龄均具有成本效益。
要点
- 在年龄依赖性主要骨质疏松性骨折干预阈值下,仿制阿仑膦酸钠自65岁起具有成本效益。
- 在髋部骨折干预阈值下,完全依从和真实世界依从分别自60岁和65岁起具有成本效益。
- 仅在固定主要骨质疏松性骨折阈值14%和髋部骨折阈值3.5%时,阿仑膦酸钠在任何年龄均具有成本效益。
核心结论
- 本研究提示,新加坡女性在年龄依赖性FRAX®干预阈值下自65岁起使用阿仑膦酸钠治疗具有成本效益。
- 识别50岁以上任何年龄的10年主要骨质疏松性骨折风险为14%或髋部骨折风险为3.5%的女性,将导致资源的有效利用。
- 基于FRAX®的高骨折概率患者获得具有成本效益的治疗机会,可能有助于减轻新加坡日益增长的骨质疏松性骨折负担。
研究设计与样本
- 采用经验证的马尔可夫微观模拟模型,估算仿制阿仑膦酸钠相比不治疗的终身医疗成本(2019年新加坡元)每质量调整生命年。
- 研究对象为新加坡50岁以上女性,骨折发生率和成本数据来自卫生部及先前发表的新加坡研究。
- 成本效益阈值设为每获得1个质量调整生命年62500新加坡元,保守基于新加坡人均国内生产总值的0.7倍。
主要发现
- 在完全依从假设下,主要骨质疏松性骨折干预阈值自65岁起具有成本效益;髋部骨折干预阈值自60岁起具有成本效益。
- 在真实世界依从假设下,主要骨质疏松性骨折干预阈值自65岁起具有成本效益;髋部骨折干预阈值自65岁起具有成本效益。
- 在50岁以上人群中,阿仑膦酸钠需在主要骨质疏松性骨折干预阈值14%和髋部骨折干预阈值3.5%时才具有成本效益。
关键数值与推荐
- 成本效益阈值:每获得1个质量调整生命年62500新加坡元(基于新加坡人均国内生产总值的0.7倍)。
- 年龄依赖性主要骨质疏松性骨折干预阈值自65岁起具有成本效益(完全依从和真实世界依从)。
- 年龄依赖性髋部骨折干预阈值在完全依从下自60岁起、真实世界依从下自65岁起具有成本效益。
- 固定主要骨质疏松性骨折干预阈值14%和髋部骨折干预阈值3.5%时,阿仑膦酸钠在50岁以上任何年龄均具有成本效益。
临床怎么用
- 本研究提示,新加坡女性在年龄依赖性FRAX®干预阈值下自65岁起使用阿仑膦酸钠治疗具有成本效益。
- 识别50岁以上任何年龄的10年主要骨质疏松性骨折风险为14%或髋部骨折风险为3.5%的女性,将导致资源的有效利用。
- 基于FRAX®的高骨折概率患者获得具有成本效益的治疗机会,可能有助于减轻新加坡日益增长的骨质疏松性骨折负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Cost-effectiveness analysis of FRAX® intervention thresholds (ITs) in Singaporean women > 50 years of age showed that generic alendronate was cost-effective at age-dependent major osteoporotic fracture (MOF) IT from the ages of 65 years for both full and real-world adherence whilst hip fracture (HF) ITs were cost-effective from the ages of 60 and 65 years. Alendronate was cost-effective irrespective of age only at fixed MOF IT of 14% and HF IT of 3.5%. INTRODUCTION: FRAX®-based intervention thresholds (ITs) were recently identified for osteoporosis management in Singapore. This study aimed to assess the cost-effectiveness of ITs in Singaporean women over the age of 50 years. METHODS: A validated Markov microsimulation model was used to estimate the lifetime healthcare costs (SGD2019) per quality-adjusted life-years (QALY) of generic alendronate compared with no treatment. Cost-effectiveness of age-dependent FRAX® major osteoporotic fracture (MOF) and hip fracture (HF) ITs was explored. In addition, ITs that would lead to cost-effectiveness were computed. Fracture incidence and cost data were obtained from the Ministry of Health and a previously published Singaporean study. A cost-effectiveness threshold of SGD 62,500/QALY gained was used, based conservatively on 0.7 times the Singapore GDP per capita. RESULTS: Generic alendronate was shown to be cost-effective at MOF ITs from the ages of 65 years, while HF ITs were cost-effective from the ages of 60 and 65 years, assuming full and real-world adherence, respectively. A 14% MOF and a 3.5% HF ITs were required for alendronate to be cost-effective above 50 years. CONCLUSION: This study suggests that the treatment of Singaporean women with alendronate is cost-effective at age-dependant FRAX® intervention thresholds at 65 years and older. Furthermore, identifying women at any age above 50 years with a 10-year risk of MOF or HF of 14% or 3.5% would lead to efficient use of resources. Cost-effective access to therapy for patients at high fracture probability based on FRAX® could contribute to reduce the growing burden of osteoporotic fractures in Singapore.
引用
- Chandran M, Ganesan G, Tan KB, et al. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporos Int. 2020. PMID: 32797250. doi:10.1007/s00198-020-05536-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。